Login
$CADL
$5.85 +$0.04 (0.69%) After hours

$CADL SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 8-K: Other Events

Candel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), sha...

12 Nov 2026 424B5
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition
05 Nov 2026 Form 4: Ostrovsky Maria, General Counsel

Granted 315,000 Stock Option (Right to Buy)

05 Nov 2026 Form 3: Ostrovsky Maria, General Counsel

No securities owned

02 Oct 2026 Form 4: Loggia Nicoletta, Director

Granted 380 Stock Option (Right to Buy) ($3.3K)

02 Oct 2026 Form 4: Papa Joseph C, Director

Granted 1,325 Stock Option (Right to Buy) ($11.5K)

02 Oct 2026 Form 4: Manning Paul B, Director

Granted 2,189 Stock Option (Right to Buy) ($19K)

11 Sep 2026 Form 4: Tak Paul Peter, Director

Received 125,000 shares by exercise or conversion ($194K) · Sold 220,866 shares ($2.54M) · Sold 59,379 shares ($621K)

10 Sep 2026 144
10 Sep 2026 Form 4: Zimmermann Martine, Director

Granted 64,000 Stock Option (Right to Buy)

10 Sep 2026 Form 3: Zimmermann Martine, Director

No securities owned

10 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness

09 Sep 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 Tipping the balance in favor of the immune system to fight cancer NASDAQ: CADL Corporate Presentation | September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s

19 Aug 2026 Form 4: Tyagarajan Seshu, Chief Technology Officer

Sold 7,000 shares ($84K)

17 Aug 2026 144
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support